File articles

Es viable el alta al otro día en pacientes que reciben TAVI

Next-Day Discharge after TAVR: Is It Viable?

Next-Day Discharge after TAVR: Is It Viable?

Next-day discharge after transfemoral transcatheter aortic valve replacement (TAVR) might be viable, with no major complications at 30 days or one year, compared against patients with longer hospital stay. We only have to consider a few factors that will help us choose the most adequate patients for this modality without compromising safety. One of the main advantages

La revascularización completa es beneficiosa en el IAM con shock cardiogénico

Complete Revascularization Is Beneficial in Acute MI with Cardiogenic Shock

Around half of all cases of ST-segment elevation acute myocardial infarction (STEMI) come alongside lesions in another vessel, for which the current strategy is complete revascularization in one or two steps. However, there are no large-scale studies analyzing patients who also present cardiogenic shock; we only have observational studies with inconclusive results influenced by several

Claves para mejorar la productividad en la sala de cateterismo

Keys to Productivity Improvement in the Cath Lab

The systematic reduction of inefficiencies in the catheterization laboratory (such as the improvement of lab room start times and room turnaround times) can definitely improve the productivity of a Department of Interventional Cardiology without forcing its members to stay in the facilities longer. As a matter of fact, work can be finished even faster with

¿Cuál es el pronóstico en las reintervenciones en la isquemia critica de MM.II.?

What Is the Prognosis for Reinterventions in Critical Lower Limb Ischemia?

Infrapopliteal (below the knee, BTK) percutaneous transluminal angioplasty (PTA) has been acknowledged as a useful strategy in chronic critical limb ischemia (CLI), but artery calcification severity results in considerable restenosis. Repeat PTA and the management of trophic lesions help with wound healing. However, this conduct has not been extensively assessed. This study enrolled 152 patients (175 limbs)

Luz roja para el TAVI en pacientes de bajo riesgo

Red Light for TAVR in Low Surgical Risk Patients

A new study raises an alarm against expanding transcatheter aortic valve replacement (TAVR) procedures to low surgical risk patients, since 2 year mortality seems higher in these patients with TAVR, compared to conventional surgery. This study will soon be published in Catheter Cardiovasc Interv. Expanding TAVR to low risk patients might involve risks we have not

Participe por una beca para asistir al C3 en Orlando, Florida

Win a Grant to the C3 in Orlando, Florida

From June 27th to June 30th, Orlando, Florida will hold the Complex Cardiovascular Catheter Therapeutics (C3 Conference), an event with a steadily growing number of attendees each year.   The Conference Organizing Committee grants, through SOLACI, five scholarships for professionals aiming to present their approved work or complex case.   Scholarships include the following: Congress

Apuntar a la lesión parece el secreto de la isquemia crítica

Lesion Targeting Seems to Be the Secret in Critical Ischemia

Ulcers that do not heal, thus threatening the integrity of a lower limb in patients with critical ischemia, is a main concern. Sometimes, despite successful revascularization, major amputation cannot be prevented. The anatomical description of angiosomes started in the 70s as a way of optimizing tissue grafts. Angiosomes are basically blocks of tissue that include

Routine FFR/iFR Reclassifies Treatment Strategies in Half of Cases

Routine invasive physiology assessment at time of angiography reclassifies treatment strategies in a big number of patients with lesions in 2 or 3 vessels, according to the multicenter prospective study DEFINE REAL, recently published in JACC Cardiovascular Interventions. The information obtained by measuring fractional flow reserve (FFR) or instantaneous wave free ratio (iFR) made interventionists modify their original plans in

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

What Is the Best Antiplatelet Therapy in Primary Angioplasty at 12 Months?

Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events at the expense of increased bleeding. This is an affordable cost, and the net clinical benefit supports these new antiplatelet therapies. The one-year follow-up of the PRAGUE-18 study focused on a comparison of efficacy and safety between prasugrel

Las nuevas guías de Hipertensión podrían estar a la altura de sus antecesoras

The new HTA guides 2017 could be up to their predecessors

From the first reports, back in 1920, we have studied, recognized and documented the excess of events associated with arterial hypertension. This linear relationship between the level of blood pressure and the risk of stroke, is evident in all adults beyond age, sex or race, transforming high blood pressure into the highest target of global